ijms-logo

Journal Browser

Journal Browser

Advances in Oxytocin 2.0

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Bioactives and Nutraceuticals".

Deadline for manuscript submissions: closed (15 March 2023) | Viewed by 1778

Special Issue Editor


E-Mail Website
Guest Editor
Department of Animal Environment and Health, Swedish University of Agricultural Sciences, 53223 Skara, Sweden
Interests: oxytocin; oxytocin agonists; release; effects; mechanisms of action in vitro; in vivo; clinical studies; behaviour; physiology; pharmacology; molecular biology; genetics
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Oxytocin, originally considered to be a birth and breastfeeding hormone, is currently receiving a great deal of attention, as the effect profile of oxytocin is steadily growing. New data regarding behavioral/psychological effects as well as physiological functions and pharmacological effects of oxytocin are being published. The molecular and genetic mechanisms mediating and regulating the oxytocin-related effects are also being uncovered. It is difficult to get an overview of the literature on oxytocin, because it involves so many different research topics. This motivates a Special Issue in which data on oxytocin from different research fields can be included and published together. There is often a gap between all the experimental data published regarding oxytocin and a discussion regarding their relevance for the in vivo situation or for possible clinical effects in humans.

Data on oxytocin from any topic, obtained from experimental studies in vitro, from animal experiments, and from pre-clinical studies in humans are welcome in this Special Issue. We encourage the inclusion of discussions regarding the physiological or pre-clinical relevance of the data reported in the submitted articles. Additionally, studies reporting experimental regarding oxytocin agonists are welcome. Both original articles and review articles will be included in this Special Issue.

Prof. Dr. Kerstin Uvnäs-Moberg
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • oxytocin
  • oxytocin agonists
  • release
  • effects
  • mechanisms of action in vitro
  • in vivo
  • behaviour
  • physiology
  • pharmacology
  • molecular biology
  • genetics

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

15 pages, 1653 KiB  
Article
Novel Long-Acting Oxytocin Analog with Increased Efficacy in Reducing Food Intake and Body Weight
by Clinton T. Elfers, James E. Blevins, Therese S. Salameh, Elizabeth A. Lawson, David Silva, Alex Kiselyov and Christian L. Roth
Int. J. Mol. Sci. 2022, 23(19), 11249; https://doi.org/10.3390/ijms231911249 - 24 Sep 2022
Cited by 2 | Viewed by 1400
Abstract
Oxytocin (OXT) analogues have been designed to overcome the limitation of the short half-life of the native OXT peptide. Here, we tested ASK2131 on obesity related outcomes in diet-induced obese (DIO) Sprague Dawley rats. In vitro function assays were conducted. The effects of [...] Read more.
Oxytocin (OXT) analogues have been designed to overcome the limitation of the short half-life of the native OXT peptide. Here, we tested ASK2131 on obesity related outcomes in diet-induced obese (DIO) Sprague Dawley rats. In vitro function assays were conducted. The effects of daily subcutaneous injections of ASK2131 vs. OXT and pair-feeding were assessed on food intake and body weight in vivo. ASK2131 is a longer-lasting OXT analog with improved pharmacokinetics compared to OXT (T1/2: 2.3 vs. 0.12 h). In chronic 22-day administration, ASK2131 was administered at 50 nmol/kg, while OXT doses were titrated up to 600 nmol/kg because OXT appeared to be less effective at reducing energy intake relative to ASK2131 at equimolar doses. After 22 days, vehicle-treated animals gained 4.5% body weight, OXT rats maintained their body weight, while those treated with ASK2131 declined in weight continuously over the 22-day period, leading to a 6.6 ± 1.3% reduction (mean ± standard error) compared to baseline. Compared to their pair-fed counterparts, ASK2131-treated rats showed a more pronounced reduction in body weight through most of the study. In summary, ASK2131 is a promising OXT-based therapeutic, with extended in vivo stability and improved potency leading to a profound reduction in body weight partly explained by reduced food intake. Full article
(This article belongs to the Special Issue Advances in Oxytocin 2.0)
Show Figures

Figure 1

Back to TopTop